Company Overview and News

 
China Vacuum Blood Collection Device Market, 2021 - National Industrial Policy Provides Strong Support

2017-10-10 prnewswire
The "China Vacuum Blood Collection Device Industry Report, 2017-2021" report has been added to Research and Markets' offering.

 
China Vacuum Blood Collection Device Industry Report, 2017-2021

2017-10-04 prnewswire
Along with steady improvement in economic environment, rising per-capita disposable income, greater awareness of health and larger health expenditure, the spending on examination also increases, so does the demand for vacuum blood collection tubes. The country's consumption of vacuum blood collection tubes has shown an AAGR of over 10% between 2009 and 2016, reaching 5.973 billion pieces in 2016.

 
Chinese medical devices maker to buy US-based Argon for $850 mln

2017-09-24 reuters
HONG KONG, Sept 24 (Reuters) - China’s Shandong Weigao Group Medical Polymer Co Ltd has agreed to acquire US-based and unlisted Argon Medical Devices Holdings Inc for $850 million, as part of its overseas expansion drive.

 
Global Dialyzer Market 2017-2021

2017-04-26 prnewswire
About Dialyzer The dialyzer, also known as artificial kidney, is a medical device that is used as a filter in the dialysis process for individuals suffering from renal failure. It consists of the filter membrane, which allows the impure blood to pass through and purifies the blood.

 
Sequoia Leads US$30 Million Series B for Klook Travel

2017-03-02 prnewswire
Sequoia Capital China Joins Team of Global Leading Investors as Klook Further Expands Spectrum of In-Destination Services

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...